preview

The New Drugs For Glaucoma

Decent Essays

Time to time there has been development in new drugs for glaucoma. With these new drugs comes new benefits and risks. Glaucoma being the second leading cause of blindness in the world (after cataract) (1) is expected to affect around 11 million people worldwide by 2020 (1). Most of the affected population are greater than 50 years of age, who are also expected to have other health issues. For a clinician, it becomes extremely important to understand the potential side effects of the medications before prescribing it to the patients. These adverse drug reactions can occur from the drug itself, the preservatives or the vehicle of the drug, and can be ocular or systemic. Unabsorbed topical ocular medication for glaucoma may drain out of the eye through naso-lacrimal duct and can be absorbed by conjunctiva, nasal mucosa, oropharynx, and GI mucosa (occasionally) to rise to sufficient levels in the blood to cause systemic side effect or interact with other drugs. It has been estimated that roughly 80% of an eye drop can pass through the nasal nasolacrimal duct and get absorbed into the nasal mucosa and its microvasculature. Considering that these eye drops are often used in either eyes twice or thrice a day, the systemic implications can be extremely dangerous. (8)(14)
Ocular therapeutics for Glaucoma:
These include beta-blockers, carbonic anhydrase inhibitors, alpha-1 and alpha-2 adrenergic agonists, prostaglandin analogues, miotics and combination medications. Most of these

Get Access